Provided by Tiger Trade Technology Pte. Ltd.

Biogen

201.18
+15.828.53%
Post-market: 200.00-1.1800-0.59%19:50 EST
Volume:3.40M
Turnover:670.34M
Market Cap:29.51B
PE:18.33
High:202.41
Open:187.01
Low:184.60
Close:185.36
52wk High:202.41
52wk Low:110.04
Shares:146.70M
Float Shares:146.23M
Volume Ratio:1.89
T/O Rate:2.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):10.97
EPS(LYR):11.21
ROE:7.39%
ROA:6.14%
PB:1.62
PE(LYR):17.95

Loading ...

Biogen: Solid Near-Term Execution but High-Risk Pipeline Keeps Rating at Hold

TIPRANKS
·
3 hours ago

Analysts Offer Insights on Healthcare Companies: Centene (CNC) and Biogen (BIIB)

TIPRANKS
·
3 hours ago

Biogen: Limited Near-Term Growth and Execution Risks Justify Neutral Hold Rating

TIPRANKS
·
3 hours ago

Biogen Trial Updates Test Investor Views On Pipeline Strength And Valuation

Simply Wall St.
·
Feb 07

Biogen Earnings Call: Solid 2025, Cautious 2026 Outlook

TIPRANKS
·
Feb 07

Biogen Inc. Stock Rallies 8.5%, Outperforms Peers

Dow Jones
·
Feb 07

Biogen price target raised to $196 from $165 at BMO Capital

TIPRANKS
·
Feb 07

BUZZ-U.S. STOCKS ON THE MOVE-SpyGlass, Agomab, Piper Sandler, Molina

Reuters
·
Feb 07

Stifel Nicolaus Adjusts Biogen PT to $214 From $202, Maintains Buy Rating

MT Newswires Live
·
Feb 07

BUZZ-U.S. STOCKS ON THE MOVE-Microchip, Under Armour, Avery Dennison

Reuters
·
Feb 06

Stock Track | Biogen Soars 5.13% Intraday on Strong Q4 Earnings Beat and Above-Expectations 2026 Profit Outlook

Stock Track
·
Feb 06

Biogen Shares up 1.2% After Co Forecast 2026 Profit Above Estimates

THOMSON REUTERS
·
Feb 06

Wedbush Keeps Their Hold Rating on Biogen (BIIB)

TIPRANKS
·
Feb 06

Biogen Exec Says Potential for Acceleration in Leqembi Growth Going Into 2027

THOMSON REUTERS
·
Feb 06

Biogen Exec Says Looking at Late-Stage M&a Targets No More Than Around $5 Bln to $6 Bln

THOMSON REUTERS
·
Feb 06

Biogen Exec Says Co Expects 2026 Sales for MS Products, Excluding Vumerity, to Decline by Mid Teen Percentage Versus 2025

THOMSON REUTERS
·
Feb 06

Biogen CEO Says Leqembi Iqlik Eligible for Part D Reimbursement, Won't Be Fully Reimbursed Until January 1, 2027 - Conf Call

THOMSON REUTERS
·
Feb 06

Biogen CEO Says Leqembi Preclinical Alzheimer's Study Fully Recruited, Results Expected in 2028

THOMSON REUTERS
·
Feb 06

Biogen Exec Says Co Will Approach New Launches in Europe From an Mfn Point of View, to Probably Target About Three or Four Countries to Start With

THOMSON REUTERS
·
Feb 06

Biogen Exec Says Lupus Drug Litifilimab Could Launch in 2028 IF Late‑Stage Data Are Positive

THOMSON REUTERS
·
Feb 06